General Information

Mail: University of Houston
Cullen College of Engineering
E421 Engineering Bldg 2, Houston, TX 77204-4007
Map & Driving Directions (includes parking information)
Email: info [at] egr [dot] uh [dot] edu

News

Industry and Academia Meeting at UH for Electromagnetics Conference

Printer-friendly versionSend by emailPDF version

By: 

Toby Weber
Electrical and Computer Engineering Professor Ji Chen with an electromagnetic coil designed for for brain stimulation.
Electrical and Computer Engineering Professor Ji Chen with an electromagnetic coil designed for brain stimulation.

Electromagnetics experts from around the country will gather at the University of Houston tomorrow to discuss the latest issues and advances in the field of electromagnetic compatibility.

The gathering is hosted by the Center for Electromagnetic Compatibility (CEMC), a partnership of the University of Houston and Missouri University of Science and Technology. Funded by the National Science Foundation (NSF), CEMC is dedicated to solving problems related to unintentional electromagnetic effects, which can impact the performance of electronic devices and even endanger the health of people with implanted medical devices such as pacemakers.

According to Ji Chen, professor of electrical and computer engineering at UH’s Cullen College of Engineering, roughly 50 people are expected to attend the two-day technical conference. In addition to academics from around the country, attendees will include industry researchers from companies such as Apple, IBM, Panasonic and Samsung.

Event Details:

Date & Time:
November 19, 2013 - 7:30am - November 20, 2013 - 5:30pm

Location:
Shamrock Ballroom, Hilton Hotel, University of Houston
4800 Calhoun Road,
Houston, TX

Faculty: 

Department: 

Tag: 

Related News Stories

Researcher Publishes Paper on Engineered Antibody that Targets Acute Myeloid Leukemia

Almost 19,000 new cases of acute myeloid leukemia and 10,500 deaths from the blood and bone marrow cancer could strike Americans this year, according to the American Cancer Society. Chemotherapy, when used as primary treatment, is successful in about 65 percent of patients with the cancer, and remission rates vary depending on patients’ individual characteristics, according to the organization.